Literature DB >> 30357723

Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Carlos Estevez-Fraga1, Paul Zeun1, Jose Luis López-Sendón Moreno2.   

Abstract

Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are iatrogenic consequences of antidopaminergic drugs. Both are particularly prevalent among the elderly and those with dementia. However, despite their prevalence, these disorders are often overlooked. Both entities share risk factors, physiopathological mechanisms and, to some degree, therapeutic approaches. Withdrawing the causal agent, reducing the dose or switching to a less potent antidopaminergic drug should be the first therapeutic options. Here we review both entities and emerging therapies including the recently approved drugs deutetrabenazine and valbenazine. We discuss relevant aspects for clinical practice such as new diagnostic techniques and the latest advances in the understanding of DIP and TD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30357723     DOI: 10.1007/s40266-018-0590-y

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  139 in total

Review 1.  123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.

Authors:  Olivier Rascol; Ludwig Schelosky
Journal:  Mov Disord       Date:  2009       Impact factor: 10.338

Review 2.  Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations.

Authors:  Francesco Brigo; Roberto Erro; Antonio Marangi; Kailash Bhatia; Michele Tinazzi
Journal:  Parkinsonism Relat Disord       Date:  2014-06-03       Impact factor: 4.891

3.  Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.

Authors:  Tanuja Bordia; Xiomara A Perez; Jaime Heiss; Danhui Zhang; Maryka Quik
Journal:  Neurobiol Dis       Date:  2016-02-24       Impact factor: 5.996

Review 4.  Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis.

Authors:  D Tarsy
Journal:  Clin Neuropharmacol       Date:  1983       Impact factor: 1.592

5.  Age-specific progression of nigrostriatal dysfunction in Parkinson's disease.

Authors:  Raúl de la Fuente-Fernández; Michael Schulzer; Lisa Kuramoto; Jacquelyn Cragg; Nandhagopal Ramachandiran; Wing L Au; Edwin Mak; Jess McKenzie; Siobhan McCormick; Vesna Sossi; Thomas J Ruth; Chong S Lee; Donald B Calne; A Jon Stoessl
Journal:  Ann Neurol       Date:  2011-01-18       Impact factor: 10.422

Review 6.  Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

Authors:  J M Kane; J M Smith
Journal:  Arch Gen Psychiatry       Date:  1982-04

Review 7.  Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis.

Authors:  Diederik E Tenback; Peter N van Harten; Jim van Os
Journal:  Mov Disord       Date:  2009-12-15       Impact factor: 10.338

8.  Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies.

Authors:  Hubert H Fernandez; Martha E Trieschmann; Monica A Burke; Joseph H Friedman
Journal:  J Clin Psychiatry       Date:  2002-06       Impact factor: 4.384

9.  The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.

Authors:  L Ganzini; D E Casey; W F Hoffman; A L McCall
Journal:  Arch Intern Med       Date:  1993-06-28

10.  Drug-induced parkinsonism.

Authors:  J A Van Gerpen
Journal:  Neurologist       Date:  2002-11       Impact factor: 1.398

View more
  4 in total

1.  Drug-Induced Movement Disorders and Its Associated Factors Among Patients Attending Treatment at Public Hospitals in Eastern Ethiopia.

Authors:  Tadesse Misgana; Niguse Yigzaw; Getachew Asfaw
Journal:  Neuropsychiatr Dis Treat       Date:  2020-08-17       Impact factor: 2.570

Review 2.  Tardive Dyskinesia in Older Persons Taking Antipsychotics.

Authors:  Leslie Citrome; Stuart H Isaacson; Danielle Larson; Daniel Kremens
Journal:  Neuropsychiatr Dis Treat       Date:  2021-10-14       Impact factor: 2.570

Review 3.  Treatable Hyperkinetic Movement Disorders Not to Be Missed.

Authors:  Aurélie Méneret; Béatrice Garcin; Solène Frismand; Annie Lannuzel; Louise-Laure Mariani; Emmanuel Roze
Journal:  Front Neurol       Date:  2021-12-01       Impact factor: 4.003

Review 4.  Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review.

Authors:  Sharadha Wisidagama; Abiram Selladurai; Peter Wu; Marco Isetta; Jordi Serra-Mestres
Journal:  Medicines (Basel)       Date:  2021-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.